Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Lexicon Pharmaceuticals, Inc.
LXRX
$1.88
Name : Lexicon Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $835,089,216.00
EPSttm : -0.07
finviz dynamic chart for LXRX
Lexicon Pharmaceuticals, Inc.
$1.88
0.00%
$0.00000000000000
LXRX — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

12.87

Margin Of Safety %

Put/Call OI Ratio

0.08

EPS Next Q Diff

EPS Last/This Y

-0.02

EPS This/Next Y

-0.05

Price

1.89

Target Price

3.72

Analyst Recom

1.8

Performance Q

13.25

Upside

-148.4%

Beta

1.1

Ticker: LXRX




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-05-11LXRX2.30.030.0133662
2026-05-12LXRX2.40.030.0635284
2026-05-13LXRX2.440.030.0035338
2026-05-14LXRX2.330.030.0135783
2026-05-15LXRX2.220.030.0135868
2026-05-18LXRX2.140.030.0630690
2026-05-19LXRX2.120.030.0330925
2026-05-20LXRX2.220.030.1031116
2026-05-21LXRX2.220.030.4431197
2026-05-22LXRX2.160.030.0031328
2026-05-26LXRX2.050.030.3331493
2026-05-27LXRX2.180.030.0231656
2026-05-28LXRX2.210.030.0331709
2026-05-29LXRX2.180.030.0231732
2026-06-02LXRX1.890.060.5533620
2026-06-03LXRX1.840.060.5333939
2026-06-04LXRX1.890.060.0434135
2026-06-05LXRX1.910.060.0334131
2026-06-08LXRX1.890.065.4434164
2026-06-09LXRX1.8950.080.0034654
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-05-11LXRX2.3050.0-66.2-0.18
2026-05-12LXRX2.41-650.0-57.9-0.18
2026-05-13LXRX2.44-650.0-46.0-0.18
2026-05-14LXRX2.33-650.0-41.6-0.18
2026-05-15LXRX2.23-650.0-41.9-0.16
2026-05-18LXRX2.14-602.3-42.1-0.16
2026-05-19LXRX2.12-602.3-44.2-0.16
2026-05-20LXRX2.21-602.3-47.5-0.16
2026-05-21LXRX2.22-602.3-45.3-0.16
2026-05-22LXRX2.16-602.3-42.9-0.16
2026-05-26LXRX2.06-602.3-41.4-0.16
2026-05-27LXRX2.18-602.3-49.4-0.16
2026-05-28LXRX2.21-602.3-45.8-0.16
2026-05-29LXRX2.18-602.3-44.0-0.16
2026-06-01LXRX2.08-100.0-41.6-0.16
2026-06-02LXRX1.89-100.0-38.7-0.16
2026-06-03LXRX1.84-100.0-43.1-0.16
2026-06-04LXRX1.89-100.0-47.0-0.16
2026-06-05LXRX1.91-100.0-45.4-0.16
2026-06-08LXRX1.89-100.0-44.1-0.16
2026-06-09LXRX1.89-100.0-45.5-0.16
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-05-11LXRX0.97-28.8010.25
2026-05-12LXRX0.97-28.8010.33
2026-05-13LXRX0.97-28.8010.33
2026-05-14LXRX0.97-28.8010.33
2026-05-15LXRX0.97-28.8010.33
2026-05-18LXRX0.971.7811.39
2026-05-19LXRX0.891.7811.39
2026-05-20LXRX0.891.7811.39
2026-05-21LXRX0.891.7811.39
2026-05-22LXRX0.891.7811.39
2026-05-26LXRX0.8910.1011.39
2026-05-27LXRX0.8910.1011.39
2026-05-28LXRX0.8910.1012.47
2026-05-29LXRX0.8910.1012.47
2026-06-02LXRX0.899.7712.47
2026-06-03LXRX0.899.7712.47
2026-06-04LXRX0.899.7712.47
2026-06-05LXRX0.899.7712.47
2026-06-08LXRX0.899.7712.87
2026-06-09LXRX0.869.7712.87
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.05

Avg. EPS Est. Next Quarter

-0.06

Insider Transactions

0.86

Institutional Transactions

9.77

Beta

1.1

Average Sales Estimate Current Quarter

3

Average Sales Estimate Next Quarter

3

Fair Value

Quality Score

53

Growth Score

36

Sentiment Score

61

Actual DrawDown %

70.1

Max Drawdown 5-Year %

-95.2

Target Price

3.72

P/E

Forward P/E

PEG

P/S

11.99

P/B

3.93

P/Free Cash Flow

EPS

-0.07

Average EPS Est. Cur. Y​

-0.16

EPS Next Y. (Est.)

-0.21

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-37.46

Relative Volume

0.5

Return on Equity vs Sector %

-40.3

Return on Equity vs Industry %

-24.2

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

-45.5
LXRX Healthcare
$1.88
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
0/20
Pullback
22/25
Volume
11/15
Valuation
10/20
TP/AR
3/10
Options
8/10
RSI
44.3
Range 1M
13%
Sup Dist
2.5%
🚀
Momentum Growth
Ride accelerating trends
N/A
29 /100
WEAK
Momentum
2/25
Growth
10/30
Estimates
3/20
Inst/Vol
8/15
Options
6/10
EPS Yr
-13.3%
EPS NY
-30%
52W%
66.5%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +97.9% upside
Quality
6/30
Valuation
15/30
Growth
6/25
Stability
6/10
LT Trend
0/5
Upside
+97.9%
Quality
53
Lexicon Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 81
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
LXRX

Latest News

Caricamento notizie per LXRX
stock quote shares LXRX – Lexicon Pharmaceuticals Inc. Stock Price stock today
news today LXRX – Lexicon Pharmaceuticals Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch LXRX – Lexicon Pharmaceuticals Inc. yahoo finance google finance
stock history LXRX – Lexicon Pharmaceuticals Inc. invest stock market
stock prices LXRX premarket after hours
ticker LXRX fair value insiders trading